Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03787732 · ClinicalTrials.gov registry record · Phase 4
Preventing Cardiovascular Collapse With Administration of Fluid Resuscitation During Induction and Intubation
A Phase 4 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,067
- Enrollment target
NCT03787732: Completed Phase 4 study, sponsored by Vanderbilt University Medical Center.
NCT03787732 is a Phase 4 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 1,067 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (106% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03787732, a Phase 4 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,067 participants
- Enrollment target
Study Summary
Complications are common during tracheal intubation of critically ill patients. Nearly one in five patients undergoing intubation in the intensive care unit experiences cardiovascular collapse, defined as severe hypotension, vasopressor administration, cardiac arrest or death. Cardiovascular collapse during intubation is associated with increased resource utilization and decreased survival. Administration of 500 mL of intravenous crystalloid solution beginning prior to induction may prevent cardiovascular collapse. The only prior trial examining fluid bolus administration during intubation found no effect on cardiovascular collapse or clinical outcomes overall, but a hypothesis-generating subgroup analysis suggested potential benefit to fluid bolus administration among patients receiving positive pressure ventilation between induction and laryngoscopy. Therefore, we propose a randomized trial comparing fluid bolus administration versus none with regard to cardiovascular collapse among critically adults undergoing intubation with positive pressure ventilation between induction and laryngoscopy.
Primary Outcome
A composite endpoint defined as one or more of the following * New systolic blood pressure \< 65 mmHg between induction and 2 minutes after intubation * New or increased vasopressor between induction and 2 minutes after intubation * Cardiac arrest within 1 hour of intubation * Death within 1 hour of intubation
Interventions
- DRUG Fluid Bolus
- OTHER No Fluid Bolus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,067 participants |
| Start Date | 2019-02-01 |
| Est. Completion | 2021-06-21 |
| Phase | Phase 4 |
What the finished NCT03787732 record still lists
NCT03787732 is an interventional study that assigns participants to a tested intervention. Its 1,067 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (106% higher).
The record links to 0 conditions, and to 2 interventions - of which Fluid Bolus is the first listed.
NCT03787732 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03787732 about?
NCT03787732 is a clinical study titled "Preventing Cardiovascular Collapse With Administration of Fluid Resuscitation During Induction and Intubation". Complications are common during tracheal intubation of critically ill patients. Nearly one in five patients undergoing intubation in the intensive care unit experiences cardiovascular collapse, defined as severe hypotension, vasopressor administration, cardiac arrest or death. Cardiovascular collaps...
What is the current status of trial NCT03787732?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,067 participants. The study started on 2019-02-01. Estimated completion is 2021-06-21.
What interventions are being tested in trial NCT03787732?
The interventions under investigation include: Fluid Bolus (DRUG), No Fluid Bolus (OTHER).
Who is sponsoring clinical trial NCT03787732?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03787732's enrollment target sits among peer trials
1,067 66th of 2000 higher than 1,935 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04165798 · 1,065 participants
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
- NCT06751043 · 1,072 participants · NA
Preoperative Fasting vs. Not Fasting in Critically Ill Patients
- NCT06159673 · 1,074 participants · Phase 2
ACP-204 in Adults With Alzheimer's Disease Psychosis
- NCT05520762 · 1,060 participants · NA
Hospital Airway Resuscitation Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI